Unicycive Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Unicycive Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.02%
Gelecekteki Temettü Verimi	83.0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Sep 07

Unicycive Therapeutics GAAP EPS of -$0.24

Aug 16

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Jul 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: UNCY şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: UNCY şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Unicycive Therapeutics Piyasaya Karşı Temettü Getirisi

UNCY temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (UNCY)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (UNCY) (3 yıla kadar)	83.0%

Önemli Temettü: UNCY şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, UNCY şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: UNCY şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: UNCY herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Unicycive Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Price target increased by 8.2% to US$5.50

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Price target decreased by 12% to US$5.08

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

New major risk - Market cap size

Unicycive Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (Olc) At the National Kidney Foundation Spring Clinical Meeting

New major risk - Financial position

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Price target increased by 15% to US$5.30

Forecast to breakeven in 2026

Consensus EPS estimates fall by 71%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Unicycive Therapeutics, Inc. announced that it has received $50 million in funding

Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding

Consensus revenue estimates decrease by 11%

New minor risk - Profitability

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate

Unicycive Therapeutics Receives Non-Compliance Notices from Nasdaq

Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors

New minor risk - Profitability

Consensus EPS estimates upgraded to US$1.17 loss

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

New major risk - Shareholder dilution

No longer forecast to breakeven

Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Unicycive Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Market Value Requirement Under Nasdaq Listing Rule 5550(b)(2)

Unicycive Therapeutics, Inc. announced delayed 10-Q filing

Price target decreased by 21% to US$7.40

Consensus revenue estimates increase by 33%

Forecast to breakeven in 2025

Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Unicycive Therapeutics Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1

Unicycive Therapeutics, Inc. Reports Key Findings of Uni-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for Renazorb™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (Ckd) Patients on Dialysis

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Unicycive Therapeutics GAAP EPS of -$0.24

Unicycive Therapeutics, Inc. Receives Written Notice from the Nasdaq Stock Market, LLC

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Unicycive Therapeutics, Inc. Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Unicycive Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Unicycive Therapeutics, Inc. Receives Confirmatory Guidance on Renazorb Regulatory Pathway

Unicycive Therapeutics, Inc. has completed an IPO in the amount of $25 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin